Pear Therapeutics, Inc. is a United States-based commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O.
The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Company’s pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas.
The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 200 |
| Three Month Average Volume | 339.0K |
| High Low | |
| Fifty-Two Week High | 0.0197 USD |
| Fifty-Two Week Low | 0 USD |
| Fifty-Two Week High Date | 13 Jun 2023 |
| Fifty-Two Week Low Date | 22 May 2024 |
| Price and Volume | |
| Current Price | 0 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -3.86% |
| Thirteen Week Relative Price Change | -99.04% |
| Twenty-Six Week Relative Price Change | -99.14% |
| Fifty-Two Week Relative Price Change | -99.98% |
| Year-to-Date Relative Price Change | -10.08% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -99.00% |
| Twenty-Six Week Price Change | -99.00% |
| Five Day Price Change | 0.00% |
| Fifty-Two Week Price Change | -99.97% |
| Year-to-Date Price Change | 0.00% |
| Month-to-Date Price Change | 0.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.21776 USD |
| Book Value Per Share (Most Recent Quarter) | 0.21776 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.21776 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.21776 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.80291 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.09152 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.09004 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.54425 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.54587 USD |
| Normalized (Last Fiscal Year) | -0.49968 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.54425 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.54342 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.54425 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.54587 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.422 USD |
| Cash Per Share (Most Recent Quarter) | 0.422 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.51565 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.50731 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.83245 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -925 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -594.70% |
| Pretax Margin (Last Fiscal Year) | -594.70% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 41.75% |
| Gross Margin (Trailing Twelve Months) | 41.75% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -971.72% |
| Operating Margin (Trailing Twelve Months) | -971.72% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -594.70% |
| Net Profit Margin (Trailing Twelve Months) | -594.70% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 94.32% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 201.66% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -26.95% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -140.18% |
| EPS Change (Trailing Twelve Months) | -292.51% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 0 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -31,825,000 |
| Net Debt (Last Fiscal Year) | -31,825,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 0 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -117,365,000 |
| Free Cash Flow (Trailing Twelve Months) | -117,365,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -30 |
| Net Interest Coverage (Trailing Twelve Months) | -30 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 90 |
| Total Debt to Equity (Most Recent Quarter) | 90 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -51.66% |
| Return on Assets (Trailing Twelve Months) | -51.66% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -124.76% |
| Return on Equity (Trailing Twelve Months) | -124.76% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -77.16% |
| Return on Investment (Trailing Twelve Months) | -77.16% |
| Return on Investment (5 Year) | -99,999.99% |